DOCS Stock Recent News

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Friday.

DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company.

Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David Roman - Goldman Sachs Jailendra Singh - Truist Craig Hettenbach - Morgan Stanley Operator Good day, everyone, and welcome to the Doximity Q4 2025 Earnings Call. At this time, I will hand the call over to Perry Gold, Head of IR.

Doximity (DOCS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.25 per share a year ago.

Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook.

SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. “We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth,” said Jeff Tangney, co-founder and CEO of Doximity. “Our newsfeed, workflow, and AI tools all hit fresh highs in Q4, helping doctors save time and provide the best car.

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.

Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.

Doximity is experiencing strong user engagement growth, driven by demand from medical prescribers and pharmaceutical marketers. Pharma marketing, Doximity's largest opportunity, is fueling sustained momentum alongside the early success of new platform tools. Integrated features like the client portal drive network effects and boost customer stickiness through real-time marketing insights.